WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Early cancer detection and compassionate care helped one woman not only survive, but also reclaim her future. Sponsored by ...

Practice-changing data in endometrial cancer support checkpoint inhibitor–chemotherapy combinations, extending ...

Analysis of data from over 1.2 million US patients with gynecologic cancers between 2004 and 2020 revealed a significant shift towards surgical de-escalation, with increased use of minimally invasive ...

There is a significant gap in patients’ understanding of treatment options for gynecologic cancers, according to a survey conducted by The Harris Poll on behalf of GSK. In a poll of more than 800 ...

Shannon is an ovarian cancer survivor, and now, she acts as a champion for other women going through the same thing.

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival ...

Even for Merck’s oncology powerhouse Keytruda, the emerging role of immunotherapies in gynecological cancer treatment represents a bit of a mixed bag. While earlier this year Keytruda seemed to shine ...

An analysis of over 1.2 million gynecologic cancer cases revealed a trend towards surgical de-escalation, with researchers observing a growing shift to minimally invasive techniques and sentinel lymph ...

The UAB Division of Gynecologic Oncology (GYN/ONC) serves as a major referral center for patients with gynecologic cancers in the state of Alabama, as well as the Southeast. We are a multidisciplinary ...

For patients with metastatic disease, referrals were more often related to cancer-specific concerns, including existential or end-of-life thoughts. This reflects how emotional needs may evolve as the ...